

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors: Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Year: 2008 Sep 1

Volume: 47

Issue: 5

Pages: 674-83

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Published in final edited form as:

Clin Infect Dis. 2008 September 1; 47(5): 674–683. doi:10.1086/590566.

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Brahm H. Segal¹, Raoul Herbrecht²², David A. Stevens^{9,10}, Luis Ostrosky-Zeichner⁴, Jack Sobel⁷, Claudio Viscoli^{28,29}, Thomas J. Walsh¹², Johan Maertens³⁰, Thomas F. Patterson⁵, John R. Perfect², Bertrand Dupont²³, John R. Wingard⁸, Thierry Calandra²¹, Carol A. Kauffman⁶, John R. Graybill⁵, Lindsey R. Baden¹⁵, Peter G. Pappas¹¹, John E. Bennett¹³, Dimitrios P. Kontoyiannis³, Catherine Cordonnier²⁴, Maria Anna Viviani²⁷, Jacques Bille²⁰, Nikolaos G. Almyroudis¹, L. Joseph Wheat¹⁴, Wolfgang Graninger^{25,26}, Eric J. Bow¹⁶, Steven M. Holland¹³, Bart-Jan Kullberg^{18,19}, William E. Dismukes¹¹, and Ben E. De Pauw¹⁷

¹Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York ²Duke University Medical Center, Durham, North Carolina ³The University of Texas M. D. Anderson Cancer Center, San Antonio ⁴University of Texas Health Science Center at Houston, San Antonio ⁵Department of Medicine, University of Texas Health Science Center, San Antonio ⁶University of Michigan, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Detroit, Michigan ⁷Wayne State University School of Medicine, Detroit, Michigan ⁸University of Florida College of Medicine, Gainesville ⁹Santa Clara Valley Medical Center, San Jose, California ¹⁰Stanford University Medical School, Stanford, California ¹¹Department of Medicine,

Reprints or correspondence: Dr. Brahm H. Segal, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY 14263 (E-mail: brahm.segal@roswellpark.org).

Potential conflicts of interest. B.H.S. has served on speakers' bureaus for Merck and Pfizer and on advisory committees for Pfizer, Berlex, and Schering Plough. B.E.d.P. has served on speakers' bureaus for Gilead, Merck, and Pfizer and on the advisory board for Basilea Pharmaceutical. J.R.P. has served on advisory boards for Schering-Plough, Enzon, Astellas, Merck, and Pfizer. D.P.K. has served on advisory boards for Schering-Plough, Pfizer, Astellas, Enzon, and Merck. C.A.K. has served on speakers' bureaus for or received research grants from Merck, Schering-Plough, and Astellas. L.O.-Z. has received research grants from Astellas, Merck, Pfizer, Associates of Cape Cod, and Rocheby and has served on speakers' bureaus for Astellas, Merck, Pfizer, Enzon, and Gilead. J.R.W. has served as a consultant for Merck, Pfizer, and Schering-Plough and has served on the speakers' bureaus for or received honoraria from Merck, Pfizer, Schering-Plough, and MGI Pharma. J.R.G. has served on the speakers' bureau for Merck; has received research funding from Merck and Schering-Plough; has served as a consultant for Merck, Schering-Plough, F2G, and Nektar; and has served on the advisory board for Schering-Plough. D.A.S. has served on advisory boards for Enzon and Gilead. L.J.W. is the President of MiraVista Diagnostics/MiraBella Technologies, which manufactures *Histoplasma* and *Aspergillus* antigen tests. E.J.B. has received research grants from Pfizer, Schering-Plough, Astellas, Wyeth, and Amgen and has worked as a consultant for Pfizer, Schering-Plough, Astellas, Wyeth, and Amgen. J.S. has received research grants from Pfizer, and Merck; has served on advisory boards for Merck and Pfizer; and has served on speakers' bureaus for Merck, Pfizer, and Schering-Plough. C.C. has received research grants from Pfizer, Merck Sharp & Dohme-Chibret, Gilead, and Schering-Plough and has served as a consultant for Gilead, Schering-Plough, and Zeneus Pharma. C.V. has served on speakers' bureaus for Merck, Pfizer, Schering-Plough, and Gilead; has served on advisory boards for Merck, Pfizer, Schering-Plough, Gilead, and Astellas; and has received research grants from Gilead, Abbott, Boe-heringer-Ingelheim, and Pfizer. P.G.P. has received research grants from Merck, Pfizer, SPRI, and Astellas; has served on speakers' bureaus for Merck, Pfizer, and Astellas; and has been an ad hoc advisor for Merck, SPRI, Pfizer, Astellas, Novartis, and Eisai. J.M. has served on advisory boards for Pfizer, Gilead, Merck Sharp & Dohme, Schering-Plough, Zeneus, and Astellas. B.-J.K. has served as a consultant for Basilea, F2G, Novartis, Pfizer, and Schering-Plough and has served on speakers' bureaus for MSD, Pfizer, and Schering-Plough. T.F.P. has served as a consultant for Merck, Pfizer, Schering-Plough, Basilea, Nektar Therapeutics, and Stiefel Laboratories and has served on speakers' bureaus for Merck and Pfizer. T.C. has received research grants from Merck Sharp & Dohme-Chibret, Essex Schering, Roche Diagnostics, Wako, and BioRad and has served as a consultant for Merck Sharp & Dohme-Chibret, Pfizer, Novartis, Essex Schering, Roche Diagnostics, and Cephalon. B.D. has served as a consultant for Schering-Plough, Astellas, Merck, Valeant, and BioAlliance. All other authors: no conflicts.

University of Alabama at Birmingham¹² Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland¹³ Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland¹⁴ MiraVista Diagnostics/ MiraBella Technologies, Indianapolis, Indiana¹⁵ Division of Infectious Diseases, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, Massachusetts¹⁶ CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada¹⁷ University Medical Center St. Raboud, Nijmegen, The Netherlands¹⁸ Department of Medicine, Nijmegen University Medical Center, Nijmegen, The Netherlands¹⁹ Raboud University Nijmegen Medical Center, Nijmegen, The Netherlands²⁰ Institute of Microbiology University Hospital, Lausanne, Switzerland²¹ Infectious Disease Service/Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland²² Department of Hematology and Oncology, Hospital de Hautepierre, Strasbourg²³ *Maladies Infectieuses et Tropicales*, Hospital Necker, Paris, France²⁴ Henri Mondor Hospital APHP and Paris 12 University, Creteil, France²⁵ Medical University of Vienna, Vienna, Austria²⁶ Division of Infectious Diseases, University Hospital Vienna, Vienna, Austria²⁷ Università degli Studi, Department of Public Health, Microbiology, and Virology, Section of Public Health, Milan²⁸ University of Genova, Genova, Italy²⁹ Division of Infectious Diseases, San Martino University Hospital, Genova, Italy³⁰ Acute Leukemia and Hematopoietic Stem Cell Transplant Unit, Department of Hematology, University Hospital Gaithuisberg, Leuven, Belgium

Abstract

Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to *Candida* species, *Aspergillus* species and other molds, *Cryptococcus neoformans*, *Histoplasma capsulatum*, and *Coccidioides immitis*. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.

Invasive fungal diseases (IFDs) are major causes of morbidity and mortality among highly immunocompromised patients. The European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG) published guidelines on definitions of IFDs for clinical research [1,2]. Bennett et al. [3–5] previously discussed challenges in the design of antifungal trials. Our objective here is to establish consensus criteria for evaluating therapeutic responses in phase III trials of IFDs.

Although specific criteria for therapeutic success vary for the major IFDs, global response requires survival and a positive effect on fungal disease (table 1). With certain IFDs (e.g., candidemia), cure is the goal of therapy. The term, “documented clearance” is more appropriate than “sterilization,” because the yield of cultures can vary, especially while patients are receiving antifungals. In histoplasmosis and cryptococcosis, a response soon after start of therapy may be termed, “successful control of disease,” correctly implying that cure may not have been achieved. Indeed, the best proof of cure for these fungal diseases is absence of relapse after cessation of therapy. The observation period to meet this high standard for certain IFDs may involve years and would be impractical for therapeutic trials. Therefore, we attempted to strike a balance between these limitations and practical end points that can be incorporated into therapeutic trials.

The primary analysis should include all patients in the intent-to-treat (ITT) or modified intent-to-treat (MITT) groups. Completion of the assigned treatment regimen is generally a requirement for a successful outcome. However, it is also reasonable to make provision for “success with modification,” as was done in a trial that compared voriconazole with amphotericin B therapy for invasive aspergillosis in which the protocol, in effect, evaluated 2 different treatment regimens rather than 2 different drugs [6,7].

Conflicting Data

Recognizing when primary antifungal therapy fails is often not straightforward, particularly when data are inadequate or conflicting [8–10]. Protocols should ideally prespecify a rank order of the weight given to specific categories of data, with more weight generally given to objective data (e.g., oxygen saturation) than to subjective data (e.g., presence of dyspnea), as well as to specific signs of fungal diseases (e.g., facial swelling in invasive fungal sinusitis) than to less specific signs (e.g., fever).

Discordant clinical, radiological, and/or mycological data may result from an inadequate period of evaluation. Selection of time points for assessment of response should account for the potential of early conflicting data. A competing concern is that longer periods of evaluation of response may increase the likelihood of seemingly unrelated events (e.g., relapsed malignancy) that would confound the interpretation of response to antifungal therapy. Suggested minimum periods of observation for the major IFDs are included in tables 2–5.

Requirement for Survival

The majority of panel members considered survival through at least the time of assessment of the primary end point to be necessary, although not sufficient, for a successful outcome. Because mortality may result from causes seemingly unrelated to the IFD, some panel members argued that more-direct markers of response to antifungal treatment (e.g., clearance of cultures or a reduction in the level of a laboratory marker) should be used as primary end points instead of survival. Prespecified criteria for attributable mortality have been used in some studies of antifungals [11–13]. Anaissie [14] argued that, in patients with invasive aspergillosis (IA), deaths for which there is no autopsy evidence of persistent fungal disease should be considered successful outcomes in trials of antifungal agents.

Attribution of mortality is difficult in patients with medically complex cases [15], even for the minority for whom autopsies are performed. Drug toxicity may influence survival in ways not obvious to the investigator (e.g., drug-drug interactions) [16] or at autopsy. In addition, the interaction of antifungal drugs with host immunity is an area of growing interest [17–23]; such interactions cannot be encapsulated solely by fungal markers and may influence survival in ways we do not understand. Randomization is expected to balance the effect of confounding variables that affect survival in the ITT or MITT analysis.

Candidemia and Other Forms of Invasive Candidiasis

In candidemia, documented clearance of *Candida* species from the blood should be a requirement for a successful outcome. Symptoms and signs (e.g., fever) attributable to disease may persist, but such signs are nonspecific and should not, by themselves, be equated with failure. Removal of a central line may reduce the time to clearance of blood cultures in cases of candidemia [24]. However, unless the protocol prespecifies removal of intravenous catheters as a requirement for eligibility, catheter removal should not be considered in the outcome assessment. Follow-up sampling of easily accessible sites, such as CSF in patients with meningitis and persistent joint fluid in those with arthritis, should be required to evaluate therapeutic response. If follow-up samples are not obtained, the response should either be

scored as indeterminate or a failure if other signs of progressive or poorly controlled disease (e.g., multiorgan failure) occur.

The time to assess primary outcomes in candidemia should not just encompass clearance of blood but also be adequate to detect early recrudescence of candidiasis and mortality directly or indirectly related to fungal disease. We suggest a period of observation of at least 4 weeks from the time of enrollment (table 2). In the view of most of the panel members, end-of-therapy response should be avoided as a primary end point, because the time to stop therapy can be variable, and end-of-therapy successes will not capture early relapses after discontinuation of therapy.

Invasive Aspergillosis and Other Mold Diseases

Evaluation of response to therapy in invasive mold disease is difficult. In the highly immunocompromised patient, fever and localizing physical examination findings are often absent [25]. In addition, some of the clinical manifestations of IA may not necessarily indicate clinical deterioration. For example, hemoptysis is more common after neutrophil recovery [26] and may not signify refractory disease.

Evaluation of radiological responses, particularly at early time points, poses several challenges. Caillot et al. [27] performed sequential CTs on patients with neutropenia and IA. Despite administration of effective antifungal treatment, leading to a positive clinical response in most patients, the median volume of lesions increased 4-fold during the first week of therapy and remained stable during the second week. This study has implications with regard to the interpretation of results of salvage therapy in which neutropenic patients with IA could be enrolled after only 7 days of standard antifungal therapy on the basis of radiological worsening [8,28–32]. Cavitation coinciding with neutrophil recovery may also be incorrectly equated with fungal disease progression [27,33–35]. There is inadequate knowledge about the radiological evolution of IA in nonneutropenic patients who respond to antifungal therapy.

Repeated sampling of infected sites (e.g., repeated lung biopsies) to evaluate for response to therapy may not be feasible or clinically warranted. In such cases, radiological response can be equated with control of disease. Other potential problems in assessing outcome are incorrect diagnosis, mixed fungal diseases [25,36], and coexistent bacterial and fungal diseases or noninfectious diseases.

Surgery as a therapeutic modality (e.g., for invasive craniofacial mold disease) poses additional challenges for interpreting therapeutic responses, because it is generally not possible to judge the effect of drug treatment alone. We suggest judging success or failure at the prespecified time of analysis, without considering whether surgery was performed. In a secondary analysis, patients treated with drug alone versus with the drug plus surgery may be analyzed separately.

In addition to facilitating the diagnosis of IA, the galactomannan assay is also a promising therapeutic marker [13,37–40]. Boutboul et al. [38] showed that serum galactomannan index (GMI) values significantly increased in patients with IA who did not respond to antifungal therapy, whereas no significant change occurred in patients who responded to therapy. Maertens et al. [37] reported that all 24 patients with IA with persistent or increasing serum GMI values eventually died of or with IA [37]. Woods et al. [41] demonstrated the utility of serial GMI testing as a predictor of outcome in patients with multiple myeloma and IA. Miceli et al. [42] defined immune reconstitution inflammatory syndrome (IRIS) as clinical and radiological deterioration and reduction in serum GMI values coinciding with neutrophil recovery in patients with IA who subsequently cleared fungal disease without a change in therapy. Serum GMI has better performance as a diagnostic marker in patients with hematological malignancies and allogeneic hematopoietic stem cell transplant recipients than

in solid-organ transplant recipients [43], suggesting that its utility as a therapeutic marker may also be influenced by host factors.

Anaissie [14] argued that serum GMI values should be used both in practice and in clinical trials as an early marker of therapeutic response in IA. The majority of panel members considered serial GMI measurements to be a highly promising therapeutic marker but believed that it was currently premature to adopt serum GMI value as a primary mycological end point in clinical trials of IA; serum GMI monitoring should be included as a secondary end point. Serum (1→3)- β -D-glucan can be a valuable diagnostic adjunct in a number of IFDs, including invasive candidiasis and aspergillosis [2,44,45]. Data on the utility of serum (1→3)- β -D-glucan monitoring as a therapeutic marker are limited.

Clinical, radiological, and mycological end points may conflict, particularly at early time points [9,10]. In the study comparing voriconazole with amphotericin B as primary therapy for IA, the difference in successful outcomes was apparent by 6 weeks [6]. Most deaths (50 [68%] of 73) that occurred during the first 6 weeks were attributable to IA; of the 25 deaths during the second 6 weeks, only 6 (24%) were attributed to IA [11]. However, in 2 pooled trials (P041 and P02387) that evaluated posaconazole as salvage therapy for invasive mold diseases, the overall rate of concordance between treatment responses assessed at 1 and 3 months was only 42% (C. Hardalo, Schering-Plough, personal communication). The concordance between 3- and 6-month assessments showed substantial improvement (76%).

For primary therapy trials of IA, most of the panel members considered 6 weeks after enrollment to be the minimum time to assess the primary outcome end point. An analysis at week 12 or later should be included as a secondary end point. By extrapolation, this period of observation is reasonable for non-*Aspergillus* invasive mold diseases. In salvage studies, a time point of at least 12 weeks should be considered for the primary end point analysis.

Cryptococcal Meningitis

C. neoformans disease most commonly manifests as meningitis. Assessment of treatment response in cryptococcal meningitis relies on clinical and mycological criteria [46–48]. Documented clearance of CSF typically precedes the expected reduction in antigen titers in patients with a response to antifungal therapy [46] and is the “gold standard” to evaluate mycological response. CSF specimens obtained by lumbar puncture are likely to be more sensitive for recovery of organisms than are those obtained by intraventricular collection; if the initial lumbar fluid specimen yields positive results followed by a negative ventricular fluid specimen, no conclusion should be drawn. Clearance of CSF is given more weight than clinical criteria (e.g., fever and meningismus) in assessing the global response. Thus, clearance of CSF but persistence of fever or headache should be equated with at least a partial response.

IRIS results from an exuberant inflammatory response toward previously diagnosed infection or infection with incubating pathogens (e.g., mycobacterial and cytomegalovirus disease). IRIS is well described in patients with AIDS-associated cryptococcal meningitis after initiation of antiretroviral therapy and manifests with meningismus and elevated CSF opening pressures, protein levels, and WBC counts [49–51]. Repeated CSF cultures are required to distinguish IRIS from persistent or recrudescing cryptococcal disease. IRIS does not represent treatment failure.

In CNS cryptococcal disease, neurological sequelae, such as blindness and dementia, can persist indefinitely and are not due to persistent microbes. The absence of fungal disease would meet the mycological end point for a successful outcome and, in fact, could be equated with cure of disease. However, the majority of panel members considered a measurable clinical improvement to be a requisite for a successful outcome in cases of cryptococcal meningitis.

This approach is consistent with use of primary end points for therapeutic trials of bacterial meningitis that include neurological sequelae [52–57].

Repeated sampling of CSF is required to assess the therapeutic response, because clinical symptoms may not correlate with control of disease. Use of systemic corticosteroids and other immunosuppressive agents may blunt symptoms and signs of meningitis. If an additional CSF sample is not obtained, then the outcome should be scored as “indeterminate” if a clinical response occurs and as “failure” if clinical findings are unchanged or worsen. In cases of concurrent extraneural *C. neoformans* disease, a mycological response involves documented clearance of disease from involved sites if repeated sampling is feasible (e.g., blood cultures for fungemic patients).

Brouwer et al. [58] evaluated antifungal regimens in patients with AIDS-associated cryptococcal meningitis, using the rate of reduction in CSF colony-forming units within the first 2 weeks as the primary end point. Despite the low number of subjects, this study identified amphotericin B plus flucytosine as the most effective regimen. In phase I/II studies in which patient accrual is limited, such quantitative mycological end points provide valuable data. However, definitive phase III trials should include longer-term end points and be adequately powered to evaluate survival, persistent morbidity, and drug toxicity.

Endemic Mycoses

Our guidelines focus on disseminated histoplasmosis and coccidioidomycosis. Chronic fibrocavitary forms of pulmonary histoplasmosis and coccidioidomycosis may show little radiological improvement with successful drug therapy. In meningitis, clinical and mycological evidence of control of disease are requisites of a successful global response. Radiological resolution of CNS fungal lesions is rarely complete, even after years of observation. Improvement of CT and MRI findings is a more useful end point to judge success, with the caveat that improvement in edema can be associated with corticosteroid therapy. IRIS has been reported in patients with AIDS-associated histoplasmosis receiving antiretroviral therapy [59] and does not denote treatment failure.

Histoplasmosis

Clearance of blood cultures is the gold standard for mycological response in patients with histoplasmosis and positive blood culture results. However, blood cultures, including those that undergo lysis-centrifugation, are too insensitive for results to be used as the sole criterion to evaluate success. Culture results may be negative before commencement of therapy and may yield only intermittently positive results during unsuccessful therapy. Thus, clearance of positive blood cultures is necessary, but not sufficient, to determine whether an outcome is successful.

Nonculture laboratory markers are useful adjuncts in monitoring the response to systemic histoplasmosis, with the provision that these tests should be conducted using the same method and ideally in the same reference laboratory. Although results of the *Histoplasma* antigen test has not been used as a study end point in clinical trials, changes in antigen findings have paralleled those of culture in patients with positive culture results [60–62]. In patients with histoplasmosis and positive blood culture results, clearance of fungemia is a better measure of antifungal effect than is clearance of antigen [63]. However, reduction in antigen levels could be used as a mycological end point in patients with negative blood culture results and as additional evidence of response in patients with positive culture results. Using a conservative measure, a decrease in the serum antigen level by at least 50% during the first 3 months of therapy relative to the baseline level can be equated with a positive mycological response. In patients whose antigen levels have decrease with therapy, a subsequent increase of $\geq 20\%$ raises

concern about relapse [64]. Antigen levels were evaluated principally in AIDS-associated disseminated histoplasmosis; the predictive value of therapeutic response in other patient populations has not been established. Antigen levels in urine may not decrease for several weeks, even with effective therapy [65]; therefore, persistent antigenuria should not be equated with failure of therapy.

Coccidioidomycosis

Several trials of coccidioidomycosis used a composite scoring system to assess therapeutic response [66–70]. Points were assigned on the basis of (1) symptoms, (2) physical examination findings, (3) quantitative complement fixation titers (baseline and follow-up titers measured in the same laboratory concurrently), and (4) culture results. Numerical values were assigned on the basis of prespecified rules, and the sum of these values at reassessment was compared with baseline values, with an increasing score indicating deterioration. A successful response required a >50% reduction in abnormal baseline findings \leq 8 months after commencement of therapy.

For patients with CNS coccidioidomycosis, life-long azole therapy is standard because of the high frequency of recrudescence if therapy is stopped [71,72]. A composite numeric outcome score using clinical and laboratory abnormalities has been applied to coccidioidal meningitis [73,74]. In one study, a response was defined as a \geq 40% reduction in baseline abnormalities without subsequent relapse during antifungal treatment [73]. A patient who had not achieved this level of improvement after 8 months was considered to be a nonresponder. For coccidioidal meningitis, CSF specimens obtained by lumbar puncture are likely to be more sensitive for recovery of organisms than are those obtained by intraventricular collection; if the initial lumbar fluid specimen yields a positive result followed by a negative ventricular fluid result, no conclusion should be drawn. Moreover, except in the rare patient with ventriculitis, ventricular fluid findings may provide an overly optimistic picture of the status of the coccidioidal disease, with lower cell counts, protein levels, and antibody titer levels and higher glucose values, compared with lumbar or cisternal fluid specimens; this could be misleading if the scoring system does not repeatedly evaluate the same CSF compartment.

Chronic soft-tissue, bone, and pulmonary disease are also characteristic of coccidioidomycosis. Some of the original antifungal salvage therapy trials involved patients with persistent coccidioidomycosis [75]. Therefore, in trials of these forms of coccidioidomycosis, improvement of clinical and laboratory end points during therapy without eradication of disease may fulfill the criteria for a successful outcome. A minority of patients with coccidioidomycosis may require \geq 9 months to respond to antifungal therapy [76]; therefore, extension of the time to evaluate the primary end point to, for example, 12 months is expected to change the outcome for this subset of patients.

Future Perspectives

To enhance trial efficiency, the US Food and Drug Administration recommended use of surrogate markers that can substitute for clinical events as tools to increase diagnostic specificity and to provide objective outcome measures [77]. Future trials involving IFDs—particularly mold diseases—should include validation of laboratory assays as predictive correlates of outcome. Such studies will ideally include prespecified serial monitoring of the marker of interest measured at the same reference laboratory. Future development and validation of sensitive, non-culture-based laboratory assays (e.g., PCR) and, potentially, functional imaging modalities (e.g., positron emission tomography [78]) may facilitate both the early diagnosis of IFD and the assessment of therapeutic response.

References

1. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis* 2002;34:7–14. [PubMed: 11731939]
2. de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008;46:1813–21. [PubMed: 18462102]
3. Bennett JE, Powers J, de Pauw B, et al. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. *Clin Infect Dis* 2003;36(Suppl 3):S113–6. [PubMed: 12679894]
4. Bennett JE, Powers J, Walsh T, et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. *Clin Infect Dis* 2003;36(Suppl 3):S117–22. [PubMed: 12679895]
5. Bennett JE, Kauffman C, Walsh T, et al. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. *Clin Infect Dis* 2003;36(Suppl 3):S123–7. [PubMed: 12679896]
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002;347:408–15. [PubMed: 12167683]
7. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. *Clin Infect Dis* 2005;41:1448–52. [PubMed: 16231256]
8. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. *Clin Infect Dis* 2006;43:1449–55. [PubMed: 17083020]
9. Nucci M, Perfect JR. When primary antifungal therapy fails. *Clin Infect Dis* 2008;46:1426–33. [PubMed: 18419447]
10. Wingard JR. Learning from our failures: the antifungal treatment conundrum. *Clin Infect Dis* 2008;46:1434–5. [PubMed: 18419448]
11. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. *Cancer* 2008;112:2309–12. [PubMed: 18338758]
12. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002;347:2020–9. [PubMed: 12490683]
13. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. *J Infect Dis* 2004;190:641–9. [PubMed: 15243943]
14. Anaissie EJ. Trial design for mould-active agents: time to break the mold: aspergillosis in neutropenic adults. *Clin Infect Dis* 2007;44:1298–306. [PubMed: 17443466]
15. Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. *Biol Blood Marrow Transplant* 2007;13:1469–76. [PubMed: 18022577]
16. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is impacted by azole antifungals. *Blood* 2004;103:1557–9. [PubMed: 14504090]
17. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. *Antimicrob Agents Chemother* 2007;51:1078–81. [PubMed: 17194825]
18. Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. *J Antimicrob Chemother* 2005;55:214–22. [PubMed: 15649994]
19. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. *PLoS Pathog* 2006;2:e35. [PubMed: 16652171]
20. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. *Mycoses* 1995;38:459–65. [PubMed: 8720196]

21. Rogers PD, Kramer RE, Chapman SW, Cleary JD. Amphotericin B–induced interleukin-1 β expression in human monocytic cells is calcium and calmodulin dependent. *J Infect Dis* 1999;180:1259–66. [PubMed: 10479156]
22. Tohyama M, Kawakami K, Saito A. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. *Antimicrob Agents Chemother* 1996;40:1919–23. [PubMed: 8843304]
23. Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin modulates inflammatory responses to *Aspergillus fumigatus* through stage-specific effects on fungal β -glucan exposure. *J Infect Dis*. 2008Published online 23 May
24. Rex JH, Bennett JE, Sugar AM, et al. NIAID Mycoses Study Group and the Candidemia Study Group. Intravascular catheter exchange and duration of candidemia. *Clin Infect Dis* 1995;21:994–6. [PubMed: 8645855]
25. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. *Mycopathologia* 2005;159:181–8. [PubMed: 15770441]
26. Pagano L, Ricci P, Nosari A, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. *Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto)*. *Br J Haematol* 1995;89:500–5. [PubMed: 7734347]
27. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. *J Clin Oncol* 2001;19:253–9. [PubMed: 11134220]
28. Viscoli C. Combination therapy for invasive aspergillosis. *Clin Infect Dis* 2004;39:803–5. [PubMed: 15472811]
29. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis* 2004;39:797–802. [PubMed: 15472810]
30. Maertens J, Raad I, Petrikos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. *Clin Infect Dis* 2004;39:1563–71. [PubMed: 15578352]
31. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. *Clin Infect Dis* 2003;36:1122–31. [PubMed: 12715306]
32. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. *Clin Infect Dis* 2007;44:2–12. [PubMed: 17143808]
33. Potente G. CT findings in fungal opportunistic pneumonias: body and brain involvement. *Comput Med Imaging Graph* 1989;13:423–8. [PubMed: 2804947]
34. Gefters WB, Albelda SM, Talbot GH, Gerson SL, Cassileth PA, Miller WT. Invasive pulmonary aspergillosis and acute leukemia: limitations in the diagnostic utility of the air crescent sign. *Radiology* 1985;157:605–10. [PubMed: 4059547]
35. Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis: influence of bone marrow recovery in patients with acute leukemia. *Am Rev Respir Dis* 1985;131:115–20. [PubMed: 3966697]
36. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). *Haematologica* 2006;91:986–9. [PubMed: 16757415]
37. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. *Blood* 2001;97:1604–10. [PubMed: 11238098]
38. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. *Clin Infect Dis* 2002;34:939–43. [PubMed: 11880959]

39. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating *Aspergillus fumigatus* galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. *J Clin Microbiol* 2003;41:2184–6. [PubMed: 12734275]
40. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J. *Aspergillus* antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. *Scand J Infect Dis* 2000;32:485–90. [PubMed: 11055651]
41. Woods G, Miceli MH, Graziutti ML, Zhao W, Barlogie B, Anaissie E. Serum *Aspergillus* galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. *Cancer* 2007;110:830–4. [PubMed: 17607669]
42. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. *Cancer* 2007;110:112–20. [PubMed: 17525971]
43. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. *Clin Infect Dis* 2006;42:1417–27. [PubMed: 16619154]
44. Odabasi Z, Mattiuzzi G, Estey E, et al. β -d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis* 2004;39:199–205. [PubMed: 15307029]
45. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1 \rightarrow 3) β -d-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis* 2005;41:654–9. [PubMed: 16080087]
46. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. *N Engl J Med* 1997;337:15–21. [PubMed: 9203426]
47. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *Clin Infect Dis* 1999;28:291–6. [PubMed: 10064246]
48. Saag MS, Graybill RJ, Larsen RA, et al. Infectious Diseases Society of America. Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis* 2000;30:710–8. [PubMed: 10770733]
49. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. *AIDS* 2005;19:1043–9. [PubMed: 15958835]
50. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related *Cryptococcus neoformans* disease in the era of highly active antiretroviral therapy. *Clin Infect Dis* 2005;40:1049–52. [PubMed: 15825000]
51. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. *Lancet Infect Dis* 2007;7:395–401. [PubMed: 17521592]
52. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002;347:1549–56. [PubMed: 12432041]
53. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. *N Engl J Med* 1991;324:1525–31. [PubMed: 2027357]
54. Roine I, Ledermann W, Foncea LM, Banfi A, Cohen J, Peltola H. Randomized trial of four vs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery. *Pediatr Infect Dis J* 2000;19:219–22. [PubMed: 10749463]
55. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. *Pediatr Infect Dis J* 1999;18:581–90. [PubMed: 10440432]
56. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. *Antimicrob Agents Chemother* 1995;39:1140–6. [PubMed: 7625802]
57. Saez-Llorens X, Castano E, Garcia R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. *Antimicrob Agents Chemother* 1995;39:937–40. [PubMed: 7785999]

58. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. *Lancet* 2004;363:1764–7. [PubMed: 15172774]
59. Breton G, Adle-Biasette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. *AIDS* 2006;20:119–21. [PubMed: 16327328]
60. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. *Am J Med* 1995;98:336–42. [PubMed: 7709945]
61. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. *Am J Med* 1997;103:223–32. [PubMed: 9316555]
62. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. *Ann Intern Med* 2002;137:105–9. [PubMed: 12118965]
63. Wheat LJ, Connolly P, Haddad N, Le Monte A, Brizendine E, Hafner R. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. *Antimicrob Agents Chemother* 2002;46:248–50. [PubMed: 11751146]
64. Wheat LJ, Connolly-Stringfield P, Blair R, Connolly K, Garringer T, Katz BP. Histoplasmosis relapse in patients with AIDS: detection using *Histoplasma capsulatum* variety *capsulatum* antigen levels. *Ann Intern Med* 1991;115:936–41. [PubMed: 1952490]
65. Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. *Clin Infect Dis* 2004;38:1485–9. [PubMed: 15156489]
66. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. *Am J Med* 1995;98:249–56. [PubMed: 7872341]
67. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. *Ann Intern Med* 2000;133:676–86. [PubMed: 11074900]
68. Stevens DA, Stiller RL, Williams PL, Sugar AM. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. *Am J Med* 1983;74:58–63. [PubMed: 6295153]
69. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400- and 800-mg doses and observations at higher doses. *Am J Med* 1988;84:603–10. [PubMed: 3279775]
70. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. NIAID Mycoses Study Group. *Am J Med* 1990;89:282–90. [PubMed: 2168126]
71. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Infectious Diseases Society of America. Practice guideline for the treatment of coccidioidomycosis. *Clin Infect Dis* 2000;30:658–61. [PubMed: 10770727]
72. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for *Coccidioides immitis* meningitis? *Ann Intern Med* 1996;124:305–10. [PubMed: 8554225]
73. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. *Ann Intern Med* 1993;119:28–35. [PubMed: 8498760]
74. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. *Ann Intern Med* 1990;112:108–12. [PubMed: 2153012]
75. Stevens DA. Miconazole in the treatment of coccidioidomycosis. *Drugs* 1983;26:347–54. [PubMed: 6354686]
76. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for non-meningeal coccidioidomycosis: clinical and laboratory observations. *J Am Acad Dermatol* 1990;23:593–601. [PubMed: 2170479]

77. Gottlieb, S. Remarks on adaptive trial design. Proceedings of the 2006 Conference on Adaptive Trial Design; Washington, DC. 10 July 2006; [1 September 2007]. Available at: <http://www.fda.gov/oc/speeches/2006/trialdesign0710.html>
78. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. *Med Mycol* 2008;46:23–9. [PubMed: 18297544]

Table 1
General criteria for global responses to antifungal therapy

| Outcome, response | Criteria |
|-------------------------------|--|
| Success | |
| Complete response | Survival within the prespecified period of observation, resolution of all attributable symptoms and signs of disease and radiological abnormalities, and mycological evidence of eradication of disease |
| Partial response | Survival within the prespecified period of observation, improvement in attributable symptoms and signs of disease and radiological abnormalities, and evidence of clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker |
| Failure | |
| Stable response ^a | Survival within the prespecified period of observation and minor or no improvement in fungal disease, but no evidence of progression, as determined on the basis of a composite of clinical, radiological, and mycological criteria |
| Progression of fungal disease | Evidence of progressive fungal disease based on a composite of clinical, radiological, and mycological criteria |
| Death | Death during the prespecified period of evaluation, regardless of attribution |

^aIn certain invasive fungal diseases (e.g., invasive mold diseases), stabilization of fungal disease during periods of severe immunocompromise provides evidence of efficacy of treatment and may be a reasonable short-term therapeutic goal until immune recovery occurs.

Table 2
Responses to antifungal therapy in patients with candidemia and other forms of invasive candidiasis

| Outcome, response | Criteria |
|------------------------|---|
| Success | |
| Complete response | Survival and resolution of all attributable symptoms and signs of disease; plus |
| | Documented clearance of pathogen from the blood in cases of candidemia; plus |
| | Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF) |
| | If additional cultures are not feasible (e.g., in cases of candidiasis involving visceral organs), survival and resolution of all attributable symptoms and signs of disease and radiological resolution can be equated with a complete response |
| Partial response | Survival and improvement of attributable symptoms and signs of disease ^a ; plus |
| | Documented clearance of blood in cases of candidemia; plus |
| | Documented clearance of infected sites that are accessible to repeated sampling (e.g., CSF). |
| | If additional cultures are not feasible, survival and resolution of attributable symptoms and signs of disease and radiological improvement or stabilization can be equated with a partial response ^b |
| Failure | |
| Stable response | Survival and minor or no improvement in attributable symptoms and signs of disease; plus |
| | Persistent isolation of <i>Candida</i> species from blood specimens or specimens from other sterile sites; or |
| | If additional cultures are not feasible, radiological stabilization can be equated with a stable response ^b |
| Progression of disease | Persistent isolation of <i>Candida</i> species from blood specimens or specimens from other sterile sites in association with worsening clinical symptoms or signs of disease (e.g., septic shock, progression of hematogenous cutaneous candidiasis); or |
| | New sites of disease or worsening of preexisting lesions radiologically (e.g., those observed in chronic disseminated candidiasis) in association with clinical deterioration |
| Death | Death during the prespecified period of evaluation regardless of attribution |

NOTE. The minimum period of observation is 4 weeks after start of therapy. The rationale for this minimum period of evaluation is to detect relapses of disease. Relapse generally requires a positive result of a culture of a specimen of blood or of another sterile site and not simply recurrence of symptoms or signs (e.g., fever) that are generally nonspecific. In the specific cases of visceral organ involvement (e.g., endocarditis, meningitis, retinitis, or chronic disseminated candidiasis), we suggest a period of observation of at least 12 weeks after start of therapy.

^aFever without localizing symptoms or other abnormal physical examination findings is the most common manifestation of candidemia. However, because fever can result from multiple causes unrelated to candidemia, we suggest that more weight be given to documented clearance of pathogens from the blood than to resolution of fever in the global assessment of response to therapy. Thus, the scenario of persistent or recurrent fever despite clearance of blood should be assessed as at least a partial response and, therefore, equated with a successful response.

^b In visceral candidiasis (e.g., hepatosplenic candidiasis) with negative blood culture results at baseline, persistent fever may be the only attributable clinical sign of candidiasis, and radiological abnormalities can persist for prolonged periods. In such situations, resolution of fever and stable radiological disease may be equated with a partial response. Laboratory markers, such as PCR and the (1→3)- β -D-glucan assay, have not been adequately validated as markers of response to therapy for invasive candidiasis.

Table 3
Responses to antifungal therapy in patients with invasive mold disease

| Outcome, response | Criteria | |
|------------------------|-------------------|--|
| Success | Complete response | Survival and resolution of all attributable symptoms and signs of disease; plus |
| | | Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated with a complete radiological response; plus |
| | | Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease involving the palate, sinuses, or cutaneous lesions) |
| Partial response | | Survival and improvement of attributable symptoms and signs of disease ^a ; plus |
| | | At least 25% reduction in diameter of radiological lesion (s); plus |
| | | Documented clearance of infected sites that are accessible to repeated sampling (e.g., mold disease involving the palate, sinuses, or cutaneous lesions) |
| | | In cases of radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion), resolution of all attributable symptoms and signs of fungal disease can be equated with a partial response |
| Failure | Stable response | Survival and minor or no improvement in attributable symptoms and signs of disease; plus |
| | | Radiological stabilization (defined as a 0%–25% reduction in the diameter of the lesion); or |
| | | Persistent isolation of mold or histological presence of invasive hyphae in infected sites |
| Progression of disease | | Worsening clinical symptoms or signs of disease; plus |
| | | New sites of disease or radiological worsening of preexisting lesions; or |
| | | Persistent isolation of mold species from infected sites |
| Death | | Death during the prespecified period of evaluation regardless of attribution |

NOTE. The minimum period of observation is at least 6 weeks in trials of primary therapy, but assessment of outcome at week 12 or later should be included as a secondary end point. For trials of salvage therapy, consider evaluation of the primary end point at least 12 weeks after enrollment.

^aClear evidence of a radiological response (reduction in diameter by at least 25% with no new sites of disease) should be given more weight than subjective, nonspecific, or difficult-to-quantify symptoms or signs of disease. Thus, in the scenario of fungal pneumonia, we suggest that radiological improvement with persistence of fever or cough should be scored as a partial response. Because radiological improvement often lags behind clinical improvement, especially if a short-term period of evaluation is employed (see Invasive Aspergillosis and Other Mold Diseases), we suggest that radiological stabilization

and resolution of all attributable symptoms and signs of disease can also be equated with a partial response. See text for discussion of serum galactomannan index as a promising correlate of therapeutic outcome.

Table 4
Responses to antifungal therapy in cryptococcal meningitis

| Outcome, response | Criteria | | |
|-------------------|------------------------|---|---|
| Success | Complete response | Survival and resolution of all attributable symptoms and signs of disease; plus | |
| | | Documented clearance of pathogen from CSF; plus | |
| | | Documented clearance of pathogen from blood in cases of bloodstream disease; plus | |
| | | Documented clearance of pathogen from other sites of disease (if additional cultures are performed); plus | |
| | | Improvement or stabilization of radiological lesions if present (e.g., CNS cryptococcoma ^a) | |
| Partial response | Partial response | Survival and improvement of attributable symptoms and signs of disease; plus | |
| | | Documented clearance of pathogen from CSF; plus | |
| | | Documented clearance of pathogen from blood in cases of bloodstream disease; plus | |
| | | Documented clearance of pathogen from other sites of disease if additional cultures are performed; plus | |
| | | Improvement or stabilization in radiological lesions if present at baseline | |
| Failure | Stable response | Survival and minor or no improvement in attributable symptoms and signs of disease; plus | |
| | | Persistently positive results of cultures of CSF specimens or specimens of other infected sites | |
| | Progression of disease | Progression of disease | Worsening clinical symptoms or signs of disease plus |
| | | | Persistently positive results of cultures of CSF specimens or specimens of other infected sites; or |
| | | | New sites of disease or worsening of preexisting lesions radiologically |
| | Death | Death during the prespecified period of evaluation, regardless of attribution | |

NOTE. The minimum period of observation is 10 weeks after the time of initiation of study drug. The rationale for this minimum period of evaluation is that assessments of clinical and mycological responses may conflict at early time points.

^aDisappearance of cryptococcoma can take years beyond cure of cryptococcal disease. Therefore, a complete or partial response can be assessed despite persistence of these lesions.

Table 5
Responses to antifungal therapy in systemic histoplasmosis

| Outcome, response | Criteria |
|------------------------|---|
| Success | |
| Complete response | Survival and resolution of all attributable symptoms and signs of disease; plus |
| | Resolution of radiological lesion(s); persistence of only a scar or postoperative changes can be equated with a complete radiological response; plus |
| | Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF) |
| | If infected sites are not accessible to repeat sampling for cultures, clearance of <i>Histoplasma</i> antigen from serum and urine (if detected at baseline) can be used as a mycological criterion for complete response. |
| Partial response | Survival and improvement of attributable symptoms and signs of disease; plus |
| | Improvement in radiological lesions; plus |
| | Documented clearance of infected sites that are accessible to repeated sampling (e.g., blood and CSF) |
| | If infected sites are not accessible to repeated sampling for cultures, a decrease in the serum <i>Histoplasma</i> antigen level of at least 50% during the first 3 months of therapy, relative to the baseline level, can be equated with a partial mycological response |
| Failure | |
| Stable response | Survival and minor or no improvement in attributable symptoms and signs of disease; plus |
| | Radiological stabilization; or |
| | Persistently positive results of cultures of specimens from infected sites; or |
| | If infected sites are not accessible to repeated sampling for culture, lack of a decrease in the serum <i>Histoplasma</i> antigen level of at least 50% after 3 months of therapy can be equated with a stable mycological response |
| Progression of disease | Worsening clinical symptoms or signs of disease; plus |
| | New sites of disease or radiological worsening of preexisting lesions; or |
| | Persistently positive results of cultures of specimens from infected sites; or |
| | If infected sites are not accessible to repeated sampling for cultures, an increase in the serum <i>Histoplasma</i> antigen level of >20% can be a mycological criterion for worsening of disease |
| Death | Death during the prespecified period of evaluation, regardless of attribution |

NOTE. Three months from time of initiation of study drug is a suggested minimum period of observation for systemic histoplasmosis. Because some patients develop relapsed disease while receiving antifungal therapy, assessment of outcome at 12 months after initiation of study drug is suggested as a secondary end point.